A new market forecast from IndexBox projects a 7.2% compound annual growth rate for the global gluten-free collagen peptides market over 2026 to 2035, lifting its market index to roughly 185 by 2035 against a 2025 base of 100.

Collagen peptides are hydrolyzed collagen, which IndexBox defines here as a supplement powder carrying gluten-free certification and marketed for joint, skin, hair, and gut health. The gluten-free part is the thing the report says is changing: certification is moving from a niche differentiator to what the analysts call a hygiene factor, meaning a baseline expectation rather than a reason to pay more.

Where the growth actually sits

IndexBox expects the category to split in two. Volume gains concentrate in the mass and private-label tiers, where price sensitivity is high and retail penetration is still expanding, while value growth concentrates in a premium tier selling claims about bioavailability, sourcing, and multi-benefit positioning.

Functional foods and beverages are named the fastest-growing end use, with collagen going into ready-to-drink coffees, protein shakes, bars, and dairy alternatives. The report is candid that this is partly a convenience play: it lowers the barrier for consumers unwilling to prepare powders, though taste masking and heat stability still limit how fast it spreads.

Clinical substantiation as a sales tool

The most interesting line for anyone reading this as science rather than commerce is how often clinical evidence appears as a competitive asset. IndexBox lists clinical substantiation and bioavailability claims among the category's major trends, and says trust and clinical evidence are critical in the smaller clinical and medical nutrition segment, which it describes as niche but stable.

That is a market analyst saying substantiation sells, not a reviewer saying the substantiation exists. No trial, outcome figure, or published study appears anywhere in the forecast, and none is claimed. Worth holding onto when a tub on a shelf advertises clinical backing in 2030.

What the numbers are

The 7.2% figure and the 185 index are modeled projections under a baseline scenario that assumes no major regulatory disruption and a stable macroeconomic environment. IndexBox notes it uses indexed curves because full absolute volumes are not publicly disclosed, so there is no dollar or tonnage figure behind the curve.

Bottom line

The forecast describes a category normalizing: allergen-free certification as table stakes, private label eating the middle, and premium brands defending margin with sourcing and evidence claims. Whether the evidence catches up with the positioning is a separate question, and this report does not try to answer it.